Amodiaquine Derivatives as Potential Alzheimer's Disease Treatments
Author Information
Author(s): Matošević Ana, Opsenica Dejan M., Bartolić Marija, Maraković Nikola, Stoilković Andriana, Komatović Katarina, Zandona Antonio, Žunec Suzana, Bosak Anita
Primary Institution: Institute for Medical Research and Occupational Health, Zagreb, Croatia
Hypothesis
Can amodiaquine derivatives effectively inhibit human cholinesterases and serve as potential treatments for Alzheimer's disease?
Conclusion
The study identified several amodiaquine derivatives as potent inhibitors of cholinesterases, with potential applications in treating Alzheimer's disease.
Supporting Evidence
- All synthesized derivatives were potent inhibitors of both cholinesterases.
- Compound 5 was identified as the most potent AChE inhibitor.
- Most compounds were able to cross the blood-brain barrier.
- Compounds exhibited antioxidant properties comparable to standard antioxidants.
- All compounds were non-toxic towards tested cell lines at effective concentrations.
Takeaway
Scientists made new versions of a medicine called amodiaquine to see if they could help treat Alzheimer's disease by stopping certain brain chemicals from breaking down too quickly.
Methodology
The study synthesized 14 amodiaquine derivatives and tested their ability to inhibit acetylcholinesterase and butyrylcholinesterase, along with assessing their antioxidant and metal chelation properties.
Limitations
The study primarily focused on in vitro results, and further in vivo studies are needed to confirm the efficacy and safety of the compounds.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website